Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dr Sudarshan Rajagopal
With
Janssen Pharmaceutica N.V., Belgium
Recent presented but unpublished results from trials of BPA vs riociguat for inoperable CTEPH (NCT02634203) have demonstrated that BPA provides a more significant hemodynamic benefit than medical therapy. The investigators hypothesize that participants who are treated with upfront combination medical therapy followed by BPA will have significant improvements in their hemodynamics and RV-PA coupling that can be monitored over time.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Age ≥ 18 years' old
2. Diagnosis of CTEPH
3. Not a candidate for PTE
4. Candidate for BPA based on suitable anatomy and disease burden
5. Treatment-naïve (no CTEPH or pulmonary arterial hypertension (PAH)-specific medical therapies) with plans for initiation of CTEPH/PAH-specific medical therapy and treatment with BPA.
6. Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed).
You may not be if
Subjects presenting with any of the following will not be included in the trials:
1. Moderate to severe heart disease (LVEF \< 45% or severe LV Hypertrophy)
2. Sarcoidosis
3. Active cancer
4. Sickle cell anemia
5. Liver disease (Childs-Pugh class C)
6. Prisoners
7. Pregnant, planning pregnancy or lactating
8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine)
9. Contraindication to riociguat or macitentan
10. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
